

High Levels of Circulating Insulin-Like Growth Factor-I Prospective Study in a Population-Based Nonscreened Cohort

Journal of Clinical Oncology

22, 3104-3112

DOI: 10.1200/jco.2004.10.105

Citation Report

#	ARTICLE	IF	CITATIONS
1	A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model. <i>Oncogene</i> , 2005, 24, 4736-4740.	2.6	58
2	Insulin-like Growth Factor 1, Chromogranin A and Prostate Specific Antigen Serum Levels in Prostate Cancer Patients and Controls. <i>European Urology</i> , 2005, 48, 34-39.	0.9	20
3	Insulin-like growth factor I treatment for cerebellar ataxia: Addressing a common pathway in the pathological cascade?. <i>Brain Research Reviews</i> , 2005, 50, 134-141.	9.1	39
4	Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era. <i>Cancer Causes and Control</i> , 2005, 16, 255-262.	0.8	65
5	Prostate Cancer Risk Among Men with Diabetes Mellitus (Spain). <i>Cancer Causes and Control</i> , 2005, 16, 1055-1058.	0.8	48
6	Putative role of serum insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) levels in the development of prostate cancer in Arab men. <i>Prostate Cancer and Prostatic Diseases</i> , 2005, 8, 84-90.	2.0	10
7	Effect of the Synthetic Retinoid Fenretinide on Circulating Free Prostate-Specific Antigen, Insulin-Like Growth Factor-I, and Insulin-Like Growth Factor Binding Protein-3 Levels in Men with Superficial Bladder Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 2083-2088.	3.2	6
8	A Prospective Study of the Insulin-Like Growth Factor Axis in Relation with Prostate Cancer in the SU.VI.MAX Trial. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2005, 14, 2269-2272.	1.1	18
9	Prognostic value of serum markers for prostate cancer. <i>Scandinavian Journal of Urology and Nephrology</i> , 2005, 39, 64-81.	1.4	63
10	PROSTATE SPECIFIC ANTIGEN LEVELS IN YOUNG ADULTHOOD PREDICT PROSTATE CANCER RISK: RESULTS FROM A COHORT OF BLACK AND WHITE AMERICANS. <i>Journal of Urology</i> , 2005, 174, 872-876.	0.2	75
11	Biochemical and Structural Characterization of a Novel Class of Inhibitors of the Type 1 Insulin-like Growth Factor and Insulin Receptor Kinases. <i>Biochemistry</i> , 2005, 44, 9430-9440.	1.2	31
12	Novel insights into the implication of the IGF-1 network in prostate cancer. <i>Trends in Molecular Medicine</i> , 2005, 11, 52-55.	3.5	62
13	Association between body mass index and prostate cancer detection rates in Japanese urologic patients. <i>Urology</i> , 2005, 66, 130-134.	0.5	14
14	Racial and anthropometric differences in plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein-3. <i>Urology</i> , 2005, 66, 587-592.	0.5	21
15	What Can Geography Tell Us About Prostate Cancer?. <i>American Journal of Preventive Medicine</i> , 2006, 30, S7-S15.	1.6	40
16	Castration rapidly decreases local insulin-like growth factor-1 levels and inhibits its effects in the ventral prostate in mice. <i>Prostate</i> , 2006, 66, 1687-1697.	1.2	19
17	Growth factor signalling in prostatic growth: significance in tumour development and therapeutic targeting. <i>British Journal of Pharmacology</i> , 2006, 147, S144-S152.	2.7	64
18	Insulin-Like Growth Factor (IGF) family and prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 58, 124-145.	2.0	135

#	ARTICLE	IF	CITATIONS
19	Apoptosis evasion: The role of survival pathways in prostate cancer progression and therapeutic resistance. <i>Journal of Cellular Biochemistry</i> , 2006, 97, 18-32.	1.2	110
20	Recreational physical activity and risk of prostate cancer: A prospective population-based study in Norway (the HUNT study). <i>International Journal of Cancer</i> , 2006, 119, 2943-2947.	2.3	111
21	Common Genetic Variation in IGF1 and Prostate Cancer Risk in the Multiethnic Cohort. <i>Journal of the National Cancer Institute</i> , 2006, 98, 123-134.	3.0	107
22	Circulating Insulin-Like Growth Factor-I and Binding Protein-3 and Risk of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1137-1141.	1.1	59
23	Insulin-like growth factors and cancer: no role in screening. Evidence from the BUPA study and meta-analysis of prospective epidemiological studies. <i>British Journal of Cancer</i> , 2006, 95, 112-117.	2.9	64
24	The IGF Axis in Prostate Cancer. <i>Current Pharmaceutical Design</i> , 2007, 13, 719-727.	0.9	37
25	Implications for Prostate Cancer of Insulin-Like Growth Factor-I (IGF-I) Genetic Variation and Circulating IGF-I Levels. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007, 92, 4820-4826.	1.8	37
26	Potential Applications for Circulating Tumor Cells Expressing the Insulin-Like Growth Factor-I Receptor. <i>Clinical Cancer Research</i> , 2007, 13, 3611-3616.	3.2	185
27	Haplotype-Based Analysis of Common Variation in the Growth Hormone Receptor Gene and Prostate Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2007, 16, 169-173.	1.1	17
28	A mechanism to explain how regular exercise might reduce the risk for clinical prostate cancer. <i>European Journal of Cancer Prevention</i> , 2007, 16, 415-421.	0.6	52
29	Overweight/obesity and cancer genesis: More than a biological link. <i>Biomedicine and Pharmacotherapy</i> , 2007, 61, 665-678.	2.5	83
30	Lignans and Human Health. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2007, 44, 483-525.	2.7	425
31	Combined Inhibitory Effects of Green Tea Polyphenols and Selective Cyclooxygenase-2 Inhibitors on the Growth of Human Prostate Cancer Cells Both In vitro and In vivo. <i>Clinical Cancer Research</i> , 2007, 13, 1611-1619.	3.2	197
32	Molecular epidemiology of prostate cancer: hormone-related genetic loci. <i>Frontiers in Bioscience - Landmark</i> , 2007, 12, 3436.	3.0	40
33	Comprehensive evaluation of genetic variation in the IGF1 gene and risk of prostate cancer. <i>International Journal of Cancer</i> , 2007, 120, 539-542.	2.3	24
34	Insulin resistance is inversely related to prostate cancer: A prospective study in Northern Sweden. <i>International Journal of Cancer</i> , 2007, 120, 2678-2686.	2.3	84
35	SELDI-TOF MS versus prostate specific antigen analysis of prospective plasma samples in a nested case-control study of prostate cancer. <i>International Journal of Cancer</i> , 2007, 121, 615-620.	2.3	31
36	IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. <i>International Journal of Cancer</i> , 2007, 121, 2267-2273.	2.3	53

#	ARTICLE	IF	CITATIONS
37	Androgens and prostate cancer risk: A prospective study. <i>Prostate</i> , 2007, 67, 1230-1237.	1.2	29
38	Hypoxia-inducible factor-1 \pm (HIF-1 \pm) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer. <i>Prostate</i> , 2007, 67, 1354-1361.	1.2	49
39	The impact of obesity on prostate cancer. <i>World Journal of Urology</i> , 2007, 25, 491-497.	1.2	17
40	Metabolic syndrome in sub-Saharan Africa: â€œsmaller twinâ€ of a regionâ€™s prostatic diseases?. <i>International Urology and Nephrology</i> , 2008, 40, 909-920.	0.6	17
41	Lifetime total physical activity and prostate cancer risk: a population-based caseâ€“control study in Sweden. <i>European Journal of Epidemiology</i> , 2008, 23, 739-746.	2.5	31
42	Differential localization of MT1â€MMP in human prostate cancer tissue: Role of IGFâ€1R in MT1â€MMP expression. <i>Prostate</i> , 2008, 68, 463-476.	1.2	19
43	Practical Examples: Hormones. , 0, , 309-321.		0
44	Nutrition, metabolic factors and cancer risk. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2008, 22, 551-571.	2.2	64
45	Endocannabinoids in endocrine and related tumours. <i>Endocrine-Related Cancer</i> , 2008, 15, 391-408.	1.6	59
46	Glycemic Status and Risk of Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2008, 17, 628-635.	1.1	22
47	Targeted Deletion of Hepatic Igf1 in TRAMP Mice Leads to Dramatic Alterations in the Circulating Insulin-Like Growth Factor Axis but Does Not Reduce Tumor Progression. <i>Cancer Research</i> , 2008, 68, 3342-3349.	0.4	52
48	Role of Hormonal and Other Factors in Human Prostate Cancer. <i>Journal of Toxicology and Environmental Health - Part B: Critical Reviews</i> , 2008, 11, 242-259.	2.9	51
49	Insulin-like Growth Factors, Their Binding Proteins, and Prostate Cancer Risk: Analysis of Individual Patient Data from 12 Prospective Studies. <i>Annals of Internal Medicine</i> , 2008, 149, 461.	2.0	263
50	The Epidemiologic Relationship between Diabetes and Cancer. <i>Frontiers in Diabetes</i> , 2008, , 84-96.	0.4	2
52	The insulin-like growth factor system and its receptors: A potential novel anticancer target. <i>Biologics: Targets and Therapy</i> , 2008, 2, 855.	3.0	6
53	One-Carbon Metabolism and Prostate Cancer Risk: Prospective Investigation of Seven Circulating B Vitamins and Metabolites. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1538-1543.	1.1	70
54	Prostate specific antigen for early detection of prostate cancer: longitudinal study. <i>BMJ: British Medical Journal</i> , 2009, 339, b3537-b3537.	2.4	102
55	NKX3.1 Activates Expression of Insulin-like Growth Factor Binding Protein-3 to Mediate Insulin-like Growth Factor-I Signaling and Cell Proliferation. <i>Cancer Research</i> , 2009, 69, 2615-2622.	0.4	19

#	ARTICLE	IF	CITATIONS
57	Cancer Incidence in Israeli Jewish Survivors of World War II. <i>Journal of the National Cancer Institute</i> , 2009, 101, 1489-1500.	3.0	96
58	Genetic Variation in the SST Gene and its Receptors in Relation to Circulating Levels of Insulin-Like Growth Factor-I, IGFBP3, and Prostate Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2009, 18, 1644-1650.	1.1	10
59	Circulating insulin-like growth factor peptides and prostate cancer risk: A systematic review and meta-analysis. <i>International Journal of Cancer</i> , 2009, 124, 2416-2429.	2.3	222
60	Genetic and plasma variation of insulin-like growth factor binding proteins in relation to prostate cancer incidence and survival. <i>Prostate</i> , 2009, 69, 1281-1291.	1.2	24
61	Phenotypes and genotypes of insulin-like growth factor 1, IGF-binding protein-3 and cancer risk: evidence from 96 studies. <i>European Journal of Human Genetics</i> , 2009, 17, 1668-1675.	1.4	94
62	Implications of insulin-like growth factor for prostate cancer therapies. <i>International Journal of Urology</i> , 2009, 16, 161-167.	0.5	55
63	Does diabetes mellitus modify the association between 17q12 risk variant and prostate cancer aggressiveness?. <i>BJU International</i> , 2009, 104, 1200-1203.	1.3	5
64	No "Barge in" on "Clargine". <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2009, 3, 132-138.	1.8	0
65	Relationship of Insulin-Like Growth Factors System Gene Polymorphisms with the Susceptibility and Pathological Development of Hepatocellular Carcinoma. <i>Annals of Surgical Oncology</i> , 2010, 17, 1808-1815.	0.7	62
66	Relationship between serum levels of insulin-like growth factors and subsequent risk of cancer mortality: Findings from a nested case-control study within the Japan Collaborative Cohort Study. <i>Cancer Epidemiology</i> , 2010, 34, 279-284.	0.8	7
67	Insulin-Like Growth Factor I Suppresses Bone Morphogenetic Protein Signaling in Prostate Cancer Cells by Activating mTOR Signaling. <i>Cancer Research</i> , 2010, 70, 9106-9117.	0.4	25
68	Plasma Levels of Acid-Labile Subunit, Free Insulin-Like Growth Factor-I, and Prostate Cancer Risk: A Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 484-491.	1.1	16
69	Circulating steroid hormones in prostate carcinogenesis. Part 1 " Androgens. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2010, 3, 341-56.	0.3	0
70	A comprehensive analysis of common IGF1, IGFBP1 and IGFBP3 genetic variation with prospective IGF-I and IGFBP-3 blood levels and prostate cancer risk among Caucasians ". <i>Human Molecular Genetics</i> , 2010, 19, 3089-3101.	1.4	47
71	2011 and beyond. <i>Mental Health and Substance Use: Dual Diagnosis</i> , 2011, 4, 1-2.	0.5	1
72	Plasma and tissue insulin-like growth factor-I receptor (IGF-IR) as a prognostic marker for prostate cancer and anti-IGF-IR agents as novel therapeutic strategy for refractory cases: A review. <i>Molecular and Cellular Endocrinology</i> , 2011, 344, 1-24.	1.6	66
74	Nutrigenetics and Prostate Cancer: 2011 and Beyond. <i>Journal of Nutrigenetics and Nutrigenomics</i> , 2011, 4, 121-136.	1.8	10
75	Human prostate cancer xenografts in <i>lit/lit</i> mice exhibit reduced growth and androgen-independent progression. <i>Prostate</i> , 2011, 71, 525-537.	1.2	19

#	ARTICLE	IF	CITATIONS
76	Plasma insulin-like growth factor 1 is positively associated with low-grade prostate cancer in the Health Professionals Follow-up Study 1993-2004. <i>International Journal of Cancer</i> , 2011, 128, 660-667.	2.3	31
77	Dietary intakes of carbohydrates in relation to prostate cancer risk: a prospective study in the Malmö Diet and Cancer cohort. <i>American Journal of Clinical Nutrition</i> , 2012, 96, 1409-1418.	2.2	80
78	The association of diabetes and positive prostate biopsy in a US veteran population. <i>Prostate Cancer and Prostatic Diseases</i> , 2012, 15, 70-74.	2.0	20
79	Prostate Carcinogenesis with Diabetes and Androgen-Deprivation-Therapy-Related Diabetes: An Update. <i>Experimental Diabetes Research</i> , 2012, 2012, 1-8.	3.8	10
81	Insulin-like Growth Factors and Cancer. , 2012, , .		16
82	Association between Circulating Levels of IGF-1 and IGFBP-3 and Lung Cancer Risk: A Meta-Analysis. <i>PLoS ONE</i> , 2012, 7, e49884.	1.1	45
83	Periacinar Retraction Cleaving in Nonneoplastic and Neoplastic Prostatic Glands: Artifact or Molecular Involvement. <i>Pathology and Oncology Research</i> , 2012, 18, 285-292.	0.9	11
84	Combining 33 genetic variants with prostate-specific antigen for prediction of prostate cancer: Longitudinal study. <i>International Journal of Cancer</i> , 2012, 130, 129-137.	2.3	31
85	Time-regulated drug delivery system based on coaxially incorporated platelet α -granules for biomedical use. <i>Nanomedicine</i> , 2013, 8, 1137-1154.	1.7	25
86	Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1984-1993.	1.1	41
87	Association of a common genetic variant of the IGF-1 gene with event-free survival in patients with HER2-positive breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 491-498.	1.2	15
88	Metabolic Syndrome as a Peculiar Target for Management of Prostate Cancer Patients. <i>Clinical Genitourinary Cancer</i> , 2013, 11, 211-220.	0.9	17
89	Variant NKX3.1 and Serum IGF-1: Investigation of Interaction in Prostate Cancer. <i>Genes and Cancer</i> , 2013, 4, 535-545.	0.6	3
90	Evidence for the Possible Biological Significance of the igf-1 Gene Alternative Splicing in Prostate Cancer. <i>Frontiers in Endocrinology</i> , 2013, 4, 31.	1.5	28
91	Inhibition of Lung Tumorigenesis by Metformin Is Associated with Decreased Plasma IGF-I and Diminished Receptor Tyrosine Kinase Signaling. <i>Cancer Prevention Research</i> , 2013, 6, 801-810.	0.7	74
92	Urinary <i>IGF, IGFBP3 and OPN as diagnostic and prognostic biomarkers for prostate cancer.</i> <i>Biomarkers in Medicine</i> , 2013, 7, 831-841.	0.6	12
93	Exercise effects on adipokines and the IGF axis in men with prostate cancer treated with androgen deprivation: A randomized study. <i>Canadian Urological Association Journal</i> , 2013, 7, 692.	0.3	37
94	Effects of Calorie Restriction and IGF-1 Receptor Blockade on the Progression of 22Rv1 Prostate Cancer Xenografts. <i>International Journal of Molecular Sciences</i> , 2013, 14, 13782-13795.	1.8	26

#	ARTICLE	IF	CITATIONS
95	Association of Polymorphisms and Haplotypes in the Insulin-Like Growth Factor 1 Receptor (IGF1R) Gene with the Risk of Breast Cancer in Korean Women. <i>PLoS ONE</i> , 2014, 9, e84532.	1.1	27
96	Prostate cancer: the need for biomarkers and new therapeutic targets. <i>Journal of Zhejiang University: Science B</i> , 2014, 15, 16-42.	1.3	26
97	Coffee consumption and prostate cancer risk: an updated meta-analysis. <i>Cancer Causes and Control</i> , 2014, 25, 591-604.	0.8	40
98	Insulin-like growth factor receptor-1 (IGF-1R) as a target for prostate cancer therapy. <i>Cancer and Metastasis Reviews</i> , 2014, 33, 607-617.	2.7	38
99	SOCS2 mediates the cross talk between androgen and growth hormone signaling in prostate cancer. <i>Carcinogenesis</i> , 2014, 35, 24-33.	1.3	42
100	Persistent androgen receptor addiction in castration-resistant prostate cancer. <i>Journal of Hematology and Oncology</i> , 2015, 8, 128.	6.9	59
101	Novel Aspects Concerning the Functional Cross-Talk between the Insulin/IGF-I System and Estrogen Signaling in Cancer Cells. <i>Frontiers in Endocrinology</i> , 2015, 6, 30.	1.5	42
102	A Phase I Study of Continuous Oral Dosing of OSI-906, a Dual Inhibitor of Insulin-Like Growth Factor-1 and Insulin Receptors, in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 701-711.	3.2	86
103	Evidence of estrone-sulfate uptake modification in young and middle-aged rat prostate. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2015, 152, 89-100.	1.2	21
104	Antioxidant and Anticoagulant Status Were Improved by Personalized Dietary Intervention Based on Biochemical and Clinical Parameters in Cancer Patients. <i>Nutrition and Cancer</i> , 2015, 67, 1083-1092.	0.9	20
105	Lactose intolerance and risk of lung, breast and ovarian cancers: aetiological clues from a population-based study in Sweden. <i>British Journal of Cancer</i> , 2015, 112, 149-152.	2.9	48
106	A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients. <i>Prostate Cancer and Prostatic Diseases</i> , 2016, 19, 323-332.	2.0	20
108	Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysis. <i>Cancer Causes and Control</i> , 2017, 28, 497-528.	0.8	65
109	Dairy Intake During the Adolescence Period and Risk of Prostate and Breast Cancer. , 2017, , 429-434.		0
110	Glucose impairments and insulin resistance in prostate cancer: the role of obesity, nutrition and exercise. <i>Obesity Reviews</i> , 2018, 19, 1008-1016.	3.1	44
111	Carbohydrate Nutrition and the Risk of Cancer. <i>Current Nutrition Reports</i> , 2019, 8, 230-239.	2.1	33
112	Identification of metabolites associated with prostate cancer risk: a nested case-control study with long follow-up in the Northern Sweden Health and Disease Study. <i>BMC Medicine</i> , 2020, 18, 187.	2.3	21
113	Insulin-Like Growth Factor-1 (IGF-1) and Its Monitoring in Medical Diagnostic and in Sports. <i>Biomolecules</i> , 2021, 11, 217.	1.8	34

#	ARTICLE	IF	CITATIONS
114	The Role of Osteokines in Sarcopenia: Therapeutic Directions and Application Prospects. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 735374.	1.8	16
115	Genetic Polymorphisms in IGF-I and IGFBP-3 Are Associated with Prostate Cancer in the Chinese Population. <i>PLoS ONE</i> , 2014, 9, e85609.	1.1	18
116	Genetic and Dietary Determinants of Insulin-Like Growth Factor (IGF)-1 and IGF Binding Protein (BP)-3 Levels among Chinese Women. <i>PLoS ONE</i> , 2014, 9, e108934.	1.1	13
117	Prostate cancer epidemiology. <i>Frontiers in Bioscience - Landmark</i> , 2006, 11, 1388.	3.0	331
118	Epidemiology of Breast, Prostate, and Colon Cancers. <i>Nutrition and Disease Prevention</i> , 2005, , .	0.1	0
119	Somatomedin C (IGF-1), Dehydroepiandrosterone Sulphate (DHEA-S) and Hcy Metabolism in Postmenopausal African Women. <i>Journal of Medical Sciences (Faisalabad, Pakistan)</i> , 2006, 6, 734-742.	0.0	1
120	The Epidemiology of Prostate Cancer. , 2010, , 3-49.		0
121	The Role of the IGF Axis in Human Malignancy: Evidence from Epidemiological Studies and Tissue Analysis. <i>Energy Balance and Cancer</i> , 2011, , 213-242.	0.2	0
122	Epidemiology of IGF-1 and Cancer. , 2012, , 1-24.		0
124	10 Prostate Cancer. , 2017, , 231-250.		0
126	Hormonal patterns in men with prediabetes and diabetes in NHANES III: possible links with prostate cancer. <i>Cancer Causes and Control</i> , 2022, 33, 429-440.	0.8	3
128	Identification of prediagnostic metabolites associated with prostate cancer risk by untargeted mass spectrometry-based metabolomics: A case-control study nested in the Northern Sweden Health and Disease Study. <i>International Journal of Cancer</i> , 2022, 151, 2115-2127.	2.3	3
129	Obesity and prostate cancer. , 2023, , 115-128.		0
131	High adherence to Western dietary pattern and prostate cancer risk: findings from the <sc>EPIC&sc>Spain cohort. <i>BJU International</i> , 2023, 132, 272-282.	1.3	1
132	Role of tumor microenvironment in prostate cancer therapy resistance. , 2024, , 27-56.		0